Reported Adverse Effects of Electronic Cigarettes

Aug.22.2022
Reported Adverse Effects of Electronic Cigarettes
UK drug regulators received 200 reports of 556 different side effects in e-cigarette users, including fatigue, blurred vision, and constipation.

The drug regulatory agency has reported that smokers have complained that their devices leave them exhausted, with blurry vision or constipation.


The medical regulatory agency has received around 200 reports from individuals who have experienced 556 different side effects. This information comes from Getty and covers the past three years.


One user complained of having hearing issues, while another claimed that these small items had left a ringing sound in their ears.


The Administration of Drug and Healthcare Products has stated that the most common complaints include coughing, hiccupping, sore throat or hoarseness, and wheezing.


More unusual issues include two cases of dizziness - where the room spins - and three instances of blurry vision or teary eyes.


One person complains that they are tired from using electronic cigarettes, while another says that the devices make them feel lazy.


Approximately 3 million people in the United Kingdom use electronic cigarettes.


John Dunne, Chairman of the UK Vaping Industry Association, has stated that the harm caused by e-cigarettes is significantly less than that of smoking.


He added, "It is well known that adult smokers may experience side effects when transitioning from smoking to physically adapting to cessation.


The regulatory body stated that "reporting of adverse reactions does not necessarily mean that they are caused by e-cigarettes.


Statement:


This article is compiled from third-party information and is intended for industry professionals to share and learn from.


This article does not represent the views of 2FIRSTS and we are unable to confirm the authenticity and accuracy of its content. The translation of this article is intended for internal industry exchange and research purposes only.


Due to limitations in the translating ability, this article may not fully convey the exact meaning of the original text. Please refer to the original text for accurate information.


2FIRSTS maintains complete alignment with the Chinese government on all domestic, Hong Kong/Macau/Taiwan-related and foreign-related statements and positions.


All compiled information is copyright of the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

KT&G to Cancel All 10.87 Million Treasury Shares on April 23
KT&G to Cancel All 10.87 Million Treasury Shares on April 23
KT&G disclosed on April 16 that it will cancel all 10.87 million treasury shares it currently holds, with the planned cancellation amounting to about KRW 1.85 trillion,(USD 1.26 billion). The cancellation date is scheduled for April 23.
Apr.17 by 2FIRSTS.ai
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands said it will phase out its myblu vaping business in the United States, citing prolonged FDA approval timelines for new vape products. The company said it will instead focus on modern oral nicotine products in the U.S., including the expansion of its Zone brand and new flavors. While overall next-generation product revenue continued to grow, revenue from the category in the Americas declined sharply.
May.12
Thailand’s DDC Reaffirms Nicotine Pouches Are Regulated Under the Tobacco Products Control Act
Thailand’s DDC Reaffirms Nicotine Pouches Are Regulated Under the Tobacco Products Control Act
Thailand’s Department of Disease Control has warned the public not to believe claims that nicotine pouches are harmless, saying the products contain high levels of nicotine that can enter the bloodstream through the mouth lining and affect the nervous system and brain.
Apr.30 by 2FIRSTS.ai
South Korea Moves Against Synthetic Nicotine Regulatory Gap as Three Companies Face Tobacco Business Act Probe
South Korea Moves Against Synthetic Nicotine Regulatory Gap as Three Companies Face Tobacco Business Act Probe
South Korea’s Ministry of Finance and Economy said on May 4 that it requested the Daejeon Metropolitan Police Agency and Gyeonggi Nambu Provincial Police Agency to investigate three sales companies on suspicion of violating the Tobacco Business Act.
May.06 by 2FIRSTS.ai
BAT New Zealand Says Illicit Tobacco Trade Drove Nearly 29% Revenue Decline in 2025
BAT New Zealand Says Illicit Tobacco Trade Drove Nearly 29% Revenue Decline in 2025
British American Tobacco New Zealand said the illicit tobacco trade is responsible for its profit halving and revenue falling between the 2024 and 2025 financial years. Financial results filed with the Companies Office show that BAT Holdings (New Zealand) recorded 2025 revenue of NZ$180.7 million, or about US$106.95 million based on the European Central Bank’s April 27, 2026 reference rates, down from NZ$254 million, or about US$150.33 million, in 2024.
Apr.28 by 2FIRSTS.ai
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas says newly released internal FDA records show agency scientific reviewers supported authorization for several flavored G2 products before senior leadership halted them. According to documents obtained through a Freedom of Information Act request, FDA’s Office of Science first recommended marketing authorization for all eight products in December 2025 and later supported six of them in February 2026. FDA ultimately authorized only the G2 device and one tobacco-flavored pod in March.
Apr.23 by 2FIRSTS.ai